RxDoctor Payments Data

Tammy Osborn

Adult Health · Blue Springs, MONPI 1184996019

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 462 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,874in general payments, 2019–2025

Across 462 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Novo Nordisk$666
  • AstraZeneca$564
  • Merck$385
  • Bayer$327
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$7,80199%
  • Education$731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,874 in reported general payments places this provider in the 90th percentile of 555 adult health providers in Missouri.

See all adult health providers in Missouri

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$132,456
MounjaroTirzepatide72$113,723
EliquisApixaban87$80,720
JardianceEmpagliflozin74$75,090
BiktarvyBictegrav/Emtricit/Tenofov Ala13$60,068
LinzessLinaclotide39$49,434
JanuviaSitagliptin Phosphate34$45,738
FarxigaDapagliflozin Propanediol32$28,319
Tresiba Flextouch U-100Insulin Degludec50$24,955
Tresiba Flextouch U-200Insulin Degludec19$20,270
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$19,555
JanumetSitagliptin Phos/Metformin Hcl12$17,133
MyrbetriqMirabegron13$14,307
XareltoRivaroxaban17$13,711
Repatha SureclickEvolocumab16$13,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$666$132,45683 claims
Lilly USA, LLCMounjaro$1,023$113,72372 claims
Boehringer IngelheimJardiance$193$75,09074 claims
MerckJanuvia, Janumet$385$62,87146 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$564$54,68073 claims
AbbVieLinzess, Synthroid$1,686$52,12184 claims
Astellas Pharma US IncMyrbetriq$155$14,30713 claims
Johnson & JohnsonXarelto$95$13,71117 claims
GSKArexvy$190$8,42230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 555 adult health providers in Missouri.

Other adult health in Blue Springs

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →